Skip to main content
SpringerLink
Log in

Myelodysplastic Syndromes (MDS) – News from ASH 2010

  • ASH Report
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

In previous years ASH presentations regarding MDS focused on clinical trials in order to establish tailored treatment options for a significant number of patients. In contrast the main topics of the recent meeting covered new molecular insights and refined analysis of previous clinical investigations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Jankowska A, Ko M, Huang Y, et al. Impaired Hydroxylation of 5-methylcytosine in TET2 mutated patients with myeloid malignancies. Blood (ASH Annual Meeting Abstracts), 116: 3, 2010 (abstr 1)

    Google Scholar 

  • Ko M, Huang Y, Jankowska A, et al. Impaired hydroxylation of 5-methylcytosine in TET2 mutated patients with myeloid malignancies. Nature, 468: 839–843, 2010

    Article  PubMed  CAS  Google Scholar 

  • Szpurka H, Jankowska A, Przychodzen B, et al. UTX mutations and epigenetic changes in MDS/MPN and related myeloid malignancies. Blood (ASH Annual Meeting Abstracts), 116: 59, 2010 (abstr 121)

    Google Scholar 

  • Kulasekararaj A, Mohamedali A, Smith A, et al. Polycomb complex group gene mutations and their prognostic relevance in 5-Azacitidine treated myelodysplastic syndrome patients. Blood (ASH Annual Meeting Abstracts), 116: 61, 2010 (abstr 125)

    Google Scholar 

  • Makishima H, Jankowska A, Tiu R, et al. Identification of oncogenic EZH2 mutations in myelodysplastic syndromes and related myeloid malignancies. Blood (ASH Annual Meeting Abstracts), 116: 267, 2010 (abstr 607)

    Google Scholar 

  • Fenaux P, Mufti G, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol, 10(3): 223–232, 2009

    Article  PubMed  CAS  Google Scholar 

  • Itzykson R, Kosmider O, Cluzeau T, et al. Presence of TET2 mutation predicts a higher response rate to azacitidine in MDS and AML post MDS. Blood (ASH Annual Meeting Abstracts), 116: 197, 2010 (abstr 439)

    Google Scholar 

  • Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood (ASH Annual Meeting Abstracts), 116: 1628–1629, 2010 (abstr 3996)

    Google Scholar 

  • Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood, 117: 403–411, 2011

    Article  PubMed  CAS  Google Scholar 

  • Naqvi K, Suarez-Almazor M, Sardesai S, et al. Comorbidities and overall survival in Myelodysplastic Syndromes (MDS): development of a prognostic model incorporating IPSS and age with ACE-27 comorbidity index. Blood (ASH Annual Meeting Abstracts), 116: 266, 2010 (abstr 605)

    Google Scholar 

  • García R, De Miguel D, Bargay J, et al. Effectiveness of various dosage regimens of azacitidine in patients with myelodysplastic syndromes: safety and efficacy final data from the spanish azacitidine compassionate use registry. Blood (ASH Annual Meeting Abstracts), 116: 772, 2010 (abstr 1853)

    Google Scholar 

  • Prebet T, Sun Z, Ketterling R, et al. A 10 day schedule of azacitidine induces more complete cytogenetic remissions than the standard schedule in myelodysplasia and acute myeloid leukemia with myelodysplasia-related changes: Results of the E1905 US Leukemia Intergroup Study. Blood (ASH Annual Meeting Abstracts), 116: 1636, 2010 (abstr 4013)

    Google Scholar 

  • Garcia-Manero G, Gore S, Cogle C, et al. Evaluation of oral azacitidine using extended treatment schedules: A phase I study. Blood (ASH Annual Meeting Abstracts), 116: 265–266, 2010 (abstr 603)

    Google Scholar 

  • Prebet T, Gore S, Esterni B, et al. Outcome of patients (pts) treated for Myelodysplastic Syndrome (MDS) and secondary Acute Myeloid Leukemia (sAML) after azacitidine (AZA) failure. Blood (ASH Annual Meeting Abstracts), 116: 199, 2010 (abstr 443)

    Google Scholar 

  • Lin K, Reljic T, Kumar A, et al. Poor outcome of patients with Myelodysplastic Syndrome (MDS) after azacitidine treatment failure. Blood (ASH Annual Meeting Abstracts), 116: 1199–1200, 2010 (abstr 2913)

    Google Scholar 

  • Garcia-Manero G, Estey E, Jabbour E, et al. Phase II study of 5-azacitidine and vorinostat in patients (pts) with newly diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) not eligible for clinical trials because poor performance or presence of other comorbidities. Blood (ASH Annual Meeting Abstracts), 116: 266, 2010 (abstr 604)

    Google Scholar 

  • Prebet T, Gore S, Sun Z, et al. Prolonged administration of azacitidine with or without entinostat increases rate of hematologic normalization for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US leukemia intergroup trial E1905. Blood (ASH Annual Meeting Abstracts), 116: 264–265, 2010 (abstr 601)

    Google Scholar 

  • Flinn I, Lang E, Raefsky E, et al. Results of a phase II trial of panobinostat (LBH589) in refractory Myelodysplastic Syndromes (MDS) patients. Blood (ASH Annual Meeting Abstracts), 116: 1636–1637, 2010 (abstr 4015)

    Google Scholar 

  • Platzbecker U, Haase D, Braulke F, et al. A phase I study of a combination of 5-azacyitidine followed by lenalidomide in high-risk MDS or AML patients with chromosome 5 abnormalities – interim results of the "AZALE" trial. Blood (ASH Annual Meeting Abstracts), 116: 1630–1631, 2010, (abstr 4000)

    Google Scholar 

  • Boehrer S, Beyne-Rauzy O, Prebet T, et al. Interim results of a randomized phase II trial of azacitidine (AZA) ± Epo in lower risk Myelodysplastic Syndrome (MDS) resistant to an Erythropoietic Stimulating Agent (ESA) alone. Blood (ASH Annual Meeting Abstracts), 116: 784, 2010 (abstr 1880)

    Google Scholar 

  • Fenaux P, Giagounidis A, Beyne-Rauzy O, et al. Prognostic factors of long-term outcomes in low- or int-1-risk MDS with del5q treated with lenalidomide (LEN): results from a randomized phase 3 trial (MDS-004). Blood (ASH Annual Meeting Abstracts), 116: 1641, 2010 (abstr 4027)

    Google Scholar 

  • Ades L, Lebras F, Sebert M, et al. Risk of AML Evolution in lower risk MDS with del 5q treated with or without lenalidomide. A report by the Groupe Francophone des Myelodysplasies (GFM). Blood (ASH Annual Meeting Abstracts), 116: 429–430, 2010 (abstr 976)

    Google Scholar 

  • Fenaux P, Kantarjian H, Lyons R, et al. Update from an open-label extension study evaluating the long-term safety and efficacy of romiplostim in thrombocytopenic patients (Pts) with Myelodysplastic Syndromes (MDS). Blood (ASH Annual Meeting Abstracts), 116: 786, 2010 (abstr 1885)

    Google Scholar 

  • Sekeres M, Roboz G, Odenike O, et al. Preliminary results of fixed-dose oral clofarabine (CLO) in patients who have failed hypomethylating agents for the treatment of myelodysplastic syndromes (MDS). Blood (ASH Annual Meeting Abstracts), 116: 779, 2010 (abstr 1869)

    Google Scholar 

  • Gattermann N, Finelli C, Della Porta M, et al. Hematologic responses in Myelodysplastic Syndromes (MDS) patients treated with deferasirox: an EPIC post-hoc analysis using international working group (IWG) 2006 criteria. Blood (ASH Annual Meeting Abstracts), 116: 1199, 2010 (abstr 2912)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 3rd Medical Department for Hematology and Oncology, Hanusch Krankenhaus, Vienna, Austria

    T. Nösslinger & M. Pfeilstöcker

Authors
  1. T. Nösslinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Pfeilstöcker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Nösslinger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nösslinger, T., Pfeilstöcker, M. Myelodysplastic Syndromes (MDS) – News from ASH 2010. memo 4, 110–112 (2011). https://doi.org/10.1007/s12254-011-0262-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-011-0262-7

Keywords

Search

Navigation